Skip to Content
BiomedicinesBiomedicines
  • Review
  • Open Access

3 October 2023

21 Pages

Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease

,
,
,
,
,
,
and
1
Institute of Cellular Biology and Pathology, “Nicolae Simionescu” of the Romanian Academy, 050568 Bucharest, Romania
2
Pharmacology Laboratory, Department of Medicine, University of Patras, 26500 Rio Achaias, Greece
3
Internal Medicine Clinic, Department of Medicine, University of Crete, 71500 Heraklion, Greece
4
Department of Life Sciences, School of Sciences, European University Cyprus, 2404 Nicosia, Cyprus
This article belongs to the Special Issue PPARs in Health and Disease

Abstract

Peroxisome proliferator-activated receptors (PPARs) are a group of ligand-binding transcription factors with pivotal action in regulating pleiotropic signaling pathways of energetic metabolism, immune responses and cell proliferation and differentiation. A significant body of evidence indicates that the PPARα receptor is an important modulator of plasma lipid and lipoprotein metabolism, with pluripotent effects influencing the lipid and apolipoprotein cargo of both atherogenic and antiatherogenic lipoproteins and their functionality. Clinical evidence supports an important role of PPARα agonists (fibric acid derivatives) in the treatment of hypertriglyceridemia and/or low high-density lipoprotein (HDL) cholesterol levels, although the effects of clinical trials are contradictory and point to a reduction in the risk of nonfatal and fatal myocardial infarction events. In this manuscript, we provide an up-to-date critical review of the existing relevant literature.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.